Privigen 50ml IV infusion

Marketed by Dexa Medica

Ingredients in every 50 ml

Human normal immunoglobulin 5000 mg

Each package contains

1 vial of 50 ml

Other details

Dosage form:Intravenous infusion
Flavour: None

W.H.O. classification

ATC Level 1: J - Antiinfectives for systemic use
ATC Level 2: J06 - Immune Sera and Immunoglobulins
ATC Level 3: J06B - Immunoglobulins



CAUTIONThis item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.


SAFE IF PRESCRIBEDThis item is safe for use during lactation.


CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.


NOT SAFEThis item should not be used while operating heavy machinery.

Available in


Dosage information

The dosage and dosage regimen is dependent on the indication. In replacement therapy the dosage may need to be individualised for each patient depending on the pharmacokinetic and clinical response. The following dosage regimens are givens as a guideline.

Replacement therapy in primary immunodeficiency syndromes
The dosage regimen should achieve a through IgG level (measured before the next infusion) of at least 5 to 6 g/L. Three to 6 months are required after the initiation of therapy for equilibration to occur. The recommended starting dose is 0.4 to 0.8 g/kg body weight (bw) followed by at least 0.2 g/kg bw every 3 to 4 weeks.
The dose required to achieve a through level of 5 to 6 g/L is of the order of 0.2 to 0.8 g/kg bw/month. The dosage interval when steady state has been reached varies from 3 to 4 weeks. Trough levels should be measured in order to adjust the dose and dosage interval.

Replacement therapy in myelomas or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; replacement therapy in children with congenital AIDS and recurrent infections
The recommended dosage is 0.2 to 0.4g/kg bw every 3 to 4 weeks.

Replacement therapy in hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT)
The recommended dose is 0.2-0.4g/kg bw every 3-4 weeks.

Immune thrombocytopenic purpura
0.8 to 1 g/kg bw on day one, which may be repeated once within 3 days, or 0.4g/kg bw daily for 2 to 5 days. The treatment can be repeated if relapse occurs.

Guillain-Barre syndrome
0.4g/kg bw/day over 5 days. Experience in children is limited.

Kawasaki disease
1.6 to 2.0 g/kg bw should be administered in divided doses over 2 to 5 days or 2.0 g/kg bw as a single dose. Patients should receive concomitant treatment with acetylsalicylic acid.

Chronic inflammatory demyelinating polyneuropathy (CIDP)
The recommended starting dose is 2 g/kg bw divided over 2 to 5 consecutive days followed by maintenance doses of 1 g/kg bw over 1 to 2 consecutive days every 3 weeks.
The long-term therapy over 24 weeks should be subject to the physician's discretion depends on the patient's response to the maintenance therapy. The dosage regimen are adjusted according to the individual course of the disease.


Replacement therapy in
1. Primary immunodeficiency syndromes (PID) such as:
– congenital agammaglobulinaemia and hypogammaglobulinaemia
– common variable immunodeficiency
– severe combined immunodeficiency
– Wiskott-Aldrich syndrome
2. Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections
3. Children with congenital AIDS and recurrent infections
4. Hypogammaglobulinaemia in patients after allogenic haematopoietic stem cell transplantation (HSCT)

1. Immune trombocytopenia purpura (ITP) in children or Adults at high risk of bleeding or prior to surgical interventions to correct the platelet count
2. Guillain-Barre syndrome
3. Kawasaki disease
4. Chronic inflammatory demyelinating polyneuropathy (CIDP).


The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.